Role of endoscopic ultrasonography or magnetic resonance imaging for screening of pancreatic cancer in low-risk individuals

Table 1 Basic characteristics of the enrolled patients, n (%)/mean ± SD

	MRI (n = 1553)	EUS (n = 1811)	P value
Age (year)	55.1 ± 11.0	52.9 ± 10.2	0.251
Gender (male)	976 (62.8)	1101 (60.8)	0.222
Body mass index, kg/m2	22.4 ± 6.9	23.5 ± 4.2	< 0.001
Smoking	139 (8.9)	195 (10.8)	0.073
Alcohol consumption	165 (10.6)	189 (10.4)	0.889
Diabetes	87 (5.6)	125 (6.9)	0.122
Laboratory result
Hemoglobin, g/dL	14.4 ± 1.5	14.3 ± 1.6	0.299
White blood cell, 103/μL	5.6 ± 1.5	5.5 ± 1.4	0.203
Platelet, 103/μL	248.3 ± 58.6	238.2 ± 57.1	0.595
Amylase, U/L	61.7 ± 25.8	61.8 ± 21.2	0.167
GPT, U/L	27.3 ± 20.5	27.8 ± 17.8	0.411
Total bilirubin, g/dL	0.96 ± 0.46	0.97 ± 0.53	0.270
Creatinine, mg/dL	0.79 ± 0.27	0.84 ± 0.19	< 0.001
LDL, mg/dL	124.1 ± 35.4	127.9 ± 35.1	0.317
Hba1c, %	5.72 ± 0.76	5.77 ± 0.74	0.063
CA19-9, U/mL	11.7 ± 10.1	12.4 ± 11.2	0.380

MRI: Magnetic resonance imaging; EUS: Endoscopic ultrasonography; GPT: Glutamic pyruvic transaminase; LDL: Low-density lipoprotein; Hba1c: Hemoglobin A1c; CA19-9: Carbohydrate antigen 19-9.